Phase 2 Trial of Ibudilast Shows Slowing of Brain Shrinkage in Progressive MS

Patients living with primary progressive multiple sclerosis have eagerly been awaiting the results from phase 2 of the ibudilast study. It is the hope...

Surprise discovery may lead potential treatment for multiple sclerosis

Canada - A surprise finding by medical scientists may lead to the development of a possible treatment for multiple sclerosis (MS).While examining human brain...

Biogen, AbbVie yank multiple sclerosis drug Zinbryta off global market

Zinbryta (daizumab) was flagged by European regulators with a lethal safety warning over cases of encephalitis and meningoencephalitis. Evaluating the drug's "complex and evolving...

Neural Skin Cells May One Day Repair CNS Nerve Damage from Multiple Sclerosis

A personalized treatment for multiple sclerosis may be one step closer, thanks to a new study that reveals how a person's own skin cells...

Health Canada approval last week of multiple sclerosis drug ‘absolutely a game-changer’

Global News - Joseph Petrilli said he cried for a long time when he heard that Health Canada approved a new drug that could...

Multiple sclerosis ”game changer” drug gets government subsidy in Australia

Melanie Row was enjoying a family holiday on the Gold Coast in 2016 when she noticed she didn't have control of her right thumb.The...

First Patient Treated in Mapi Pharma’s Phase II Clinical Trial of GA Depot for...

NESS ZIONA, Israel, Jan. 30, 2018 (GLOBE NEWSWIRE) -- Mapi Pharma Ltd announced today that the first patient has been treated with GA Depot...

Biogen’s 8% Increase to Some MS Medications Could Provide a Boost in 2018

Market Watch reports Biogen Inc.'s BIIB, +4.90% recent price increases on multiple sclerosis drugs "could provide lift into '18," according to RBC Capital Markets...

New Inroads Against Multiple Sclerosis

JAMA recently published their interviews with two MS Specaists focusing on the medical progress against multiple sclerosis (MS) in 2017 with the approval by the...

Novartis multiple sclerosis therapy fingolimod granted FDA Breakthrough Therapy designation for pediatric MS

SOURCE Novartis- Breakthrough Therapy designation can expedite the development and review of therapies for serious conditions- In a pivotal Phase III study, oral fingolimod...

Social Media

746FollowersFollow